A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Recruiting

Phase 3

Chickenpox VaccineA Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Sponsor:

GlaxoSmithKline

Code:

NCT06740630

Conditions

Chickenpox

Eligibility Criteria

Sex: All

Age: 1

Healthy Volunteers: Accepted

Interventions

Investigational varicella vaccine_Lot 1

Investigational varicella vaccine_Lot 2

Investigational varicella vaccine_Lot 3

Marketed varicella vaccine_Lot 1

Marketed varicella vaccine_Lot 2

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-18. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2025-03-07.